KR101648019B1 - 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법 - Google Patents

비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법 Download PDF

Info

Publication number
KR101648019B1
KR101648019B1 KR1020107029686A KR20107029686A KR101648019B1 KR 101648019 B1 KR101648019 B1 KR 101648019B1 KR 1020107029686 A KR1020107029686 A KR 1020107029686A KR 20107029686 A KR20107029686 A KR 20107029686A KR 101648019 B1 KR101648019 B1 KR 101648019B1
Authority
KR
South Korea
Prior art keywords
cells
cell
differentiation
gly
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107029686A
Other languages
English (en)
Korean (ko)
Other versions
KR20110036548A (ko
Inventor
아만다 맥
제임스 톰슨
Original Assignee
셀룰러 다이내믹스 인터내셔널, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40977641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101648019(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 filed Critical 셀룰러 다이내믹스 인터내셔널, 인코포레이티드
Publication of KR20110036548A publication Critical patent/KR20110036548A/ko
Application granted granted Critical
Publication of KR101648019B1 publication Critical patent/KR101648019B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107029686A 2008-06-04 2009-06-04 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법 Active KR101648019B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5885808P 2008-06-04 2008-06-04
US61/058,858 2008-06-04
US16058409P 2009-03-16 2009-03-16
US61/160,584 2009-03-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167005088A Division KR101871192B1 (ko) 2008-06-04 2009-06-04 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법

Publications (2)

Publication Number Publication Date
KR20110036548A KR20110036548A (ko) 2011-04-07
KR101648019B1 true KR101648019B1 (ko) 2016-08-16

Family

ID=40977641

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107029686A Active KR101648019B1 (ko) 2008-06-04 2009-06-04 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법
KR1020167005088A Active KR101871192B1 (ko) 2008-06-04 2009-06-04 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167005088A Active KR101871192B1 (ko) 2008-06-04 2009-06-04 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법

Country Status (10)

Country Link
US (4) US8546140B2 (cg-RX-API-DMAC7.html)
EP (4) EP2297307B1 (cg-RX-API-DMAC7.html)
JP (5) JP2011522540A (cg-RX-API-DMAC7.html)
KR (2) KR101648019B1 (cg-RX-API-DMAC7.html)
AU (1) AU2009256202B2 (cg-RX-API-DMAC7.html)
CA (2) CA2954948A1 (cg-RX-API-DMAC7.html)
DK (1) DK2297307T3 (cg-RX-API-DMAC7.html)
ES (1) ES2587395T3 (cg-RX-API-DMAC7.html)
IL (1) IL209740A (cg-RX-API-DMAC7.html)
WO (1) WO2009149233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
CN101864392B (zh) * 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CA2684242C (en) 2007-03-23 2019-11-12 Wisconsin Alumni Research Foundation Somatic cell reprogramming
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2954948A1 (en) 2008-06-04 2009-12-10 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
CA2969377C (en) * 2008-06-13 2019-12-03 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
KR101773345B1 (ko) 2008-08-12 2017-08-31 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 ｉＰＳ 세포의 생산 방법
US8268620B2 (en) * 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP2421957B1 (en) 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
DK2548950T3 (en) 2009-06-05 2017-12-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
KR101774206B1 (ko) 2009-08-07 2017-09-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
SG10201406139RA (en) 2009-09-30 2014-11-27 Agency Science Tech & Res A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
JP5898086B2 (ja) * 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
WO2011119942A1 (en) * 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
JP2013530699A (ja) 2010-06-15 2013-08-01 セルラー ダイナミクス インターナショナル， インコーポレイテッド 生物学的応答の調査のための既製の幹細胞モデルの概要
EP2582794B2 (en) * 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US9365826B2 (en) 2010-06-18 2016-06-14 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
WO2012054935A2 (en) * 2010-10-22 2012-04-26 Salk Institute For Biological Studies Formation of hematopoietic progenitor cells from mesenchymal stem cells
CA2826386C (en) 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
CA2841165A1 (en) * 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
WO2013022022A1 (ja) * 2011-08-08 2013-02-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN103998598A (zh) 2011-10-17 2014-08-20 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
CA2858148C (en) 2011-12-05 2023-03-14 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP2826855B1 (en) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardial sheet
EP2829605B1 (en) 2012-03-21 2019-05-08 Kyoto University Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
JP6112733B2 (ja) 2012-04-06 2017-04-12 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
CN104411931B (zh) 2012-04-27 2017-03-01 日野自动车株式会社 燃烧器以及过滤器再生装置
CA2874259C (en) * 2012-05-23 2021-02-09 Kyoto University Highly efficient method for establishing induced pluripotent stem cell
US9175263B2 (en) 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
AU2014248167B2 (en) 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
WO2014170549A1 (en) * 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
WO2014197934A1 (en) 2013-06-14 2014-12-18 The University Of Queensland Renal progenitor cells
CN103333918B (zh) * 2013-06-19 2015-12-02 中山大学 一种提高猪克隆胚胎体外发育效率的方法
US10738323B2 (en) 2013-07-12 2020-08-11 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
US9988605B2 (en) 2013-12-11 2018-06-05 Korea Advanced Institute Of Science And Technology Method for preparing endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells
RU2714404C2 (ru) 2014-01-31 2020-02-14 Фэктор Байосайенс Инк. Способы и продукты для получения и доставки нуклеиновых кислот
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
AU2015249371B2 (en) 2014-04-24 2020-04-30 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN106574243B (zh) * 2014-06-27 2021-02-23 安吉克莱茵生物科学有限公司 表达腺病毒e4orf1的神经细胞及其制备方法和应用
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN106574248B (zh) 2014-08-19 2020-11-24 富士胶片细胞动力有限公司 由源自多能干细胞的细胞形成的神经网络
EP3207122B1 (en) 2014-10-14 2019-05-08 FUJIFILM Cellular Dynamics, Inc. Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN108291206B (zh) 2015-09-08 2022-07-08 富士胶片细胞动力公司 干细胞来源的视网膜色素上皮的基于macs的纯化
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
CN108350429B (zh) 2015-10-20 2022-02-25 富士胶片细胞动力公司 用于将多能干细胞定向分化为免疫细胞的方法
WO2017100313A1 (en) 2015-12-07 2017-06-15 Biotime, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells
CA3010764A1 (en) * 2016-01-12 2017-07-20 Lonza Walkersville, Inc. Methods and vectors to produce vector free induced pluripotent stem cells
EP3455346A1 (en) 2016-05-12 2019-03-20 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
AU2017313065B2 (en) 2016-08-16 2021-06-24 Fujifilm Cellular Dynamics Inc. Methods for differentiating pluripotent cells
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
DK3519558T3 (da) 2016-09-28 2023-11-13 Organovo Inc Anvendelse af modificeret nyrevæv i assays
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
AU2017359330B2 (en) 2016-11-09 2022-03-10 The United States Of America, As Represented By The Secretary Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
KR102668891B1 (ko) 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 항원-특이적 면역 이펙터 세포
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
US20190100729A1 (en) 2017-10-03 2019-04-04 Wallkill BioPharma, Inc. Treating diabetes with genetically modified beta cells
US12247226B2 (en) 2017-10-11 2025-03-11 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
WO2019204817A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
WO2020069373A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
KR20210095885A (ko) 2018-11-19 2021-08-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생분해성 조직 대체 임플란트 및 그의 용도
KR20210096638A (ko) 2018-11-28 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
EP3972617A4 (en) * 2019-05-23 2023-06-07 The McLean Hospital Corporation AUTOLOGOUS CELL REPLACEMENT THERAPY FOR PARKINSON'S DISEASE
US12410401B2 (en) 2019-06-06 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2
CN119569589A (zh) 2019-07-03 2025-03-07 菲克特生物科学股份有限公司 阳离子脂质及其用途
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
WO2021117886A1 (ja) 2019-12-12 2021-06-17 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
CA3180561A1 (en) 2020-05-29 2021-12-02 Andrew DIAS Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
AU2021280343A1 (en) 2020-05-29 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
CN116710478A (zh) 2020-10-07 2023-09-05 迈凯恩技术有限公司 冠状病毒感染性细胞及其制备方法
US20230051406A1 (en) 2020-11-13 2023-02-16 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
KR20230159550A (ko) * 2021-03-25 2023-11-21 블루록 테라퓨틱스 엘피 유도 만능 줄기 세포 수득 방법
AU2022253891A1 (en) 2021-04-07 2023-08-24 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
EP4319876A1 (en) 2021-04-07 2024-02-14 Fujifilm Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
IL307358A (en) 2021-04-07 2023-11-01 Century Therapeutics Inc Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
AU2022255166A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
CN117881777A (zh) 2021-05-26 2024-04-12 富士胶片细胞动力公司 防止多能干细胞中基因快速沉默的方法
WO2022251499A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
EP4346928A1 (en) 2021-05-28 2024-04-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
JP2024531682A (ja) 2021-09-13 2024-08-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド コミットされた心臓始原細胞の製造方法
AU2022376962A1 (en) 2021-10-29 2024-04-18 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
US20250064934A1 (en) 2021-12-29 2025-02-27 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
IL316180A (en) * 2022-04-08 2024-12-01 New York Stem Cell Found Inc Methods for producing IPSCS
EP4519319A1 (en) 2022-05-04 2025-03-12 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
CA3257424A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically modified cells expressing variants of CD16 and NKG2D and their uses
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
WO2023247532A1 (en) 2022-06-21 2023-12-28 Institut National de la Santé et de la Recherche Médicale A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
EP4594471A1 (en) 2022-09-30 2025-08-06 Fujifilm Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
EP4615876A2 (en) 2022-11-10 2025-09-17 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
US20250362218A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
DE19635568C1 (de) 1996-09-02 1998-03-26 Gsf Forschungszentrum Umwelt Vektorsysteme zur konditionalen Genexpression
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
AU6842001A (en) 2000-06-15 2001-12-24 Tanja Dominko Pluripotent mammalian cells
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20020136709A1 (en) 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
WO2003018780A1 (en) 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JP2004248505A (ja) 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
ITMI20012110A1 (it) 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
EP1468094A4 (en) * 2001-12-24 2005-01-26 Es Cell Int Pte Ltd METHOD OF TRANSDUCTING ES CELLS
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0206357D0 (en) * 2002-03-18 2002-05-01 Univ Bath Cells
US20060128018A1 (en) 2003-02-07 2006-06-15 Zwaka Thomas P Directed genetic modifications of human stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
US7465580B2 (en) 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
US7442548B2 (en) 2004-09-08 2008-10-28 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
JP4803584B2 (ja) * 2006-02-08 2011-10-26 独立行政法人産業技術総合研究所 脂質生産性の高い形質転換微生物
CA2658204A1 (en) 2006-07-07 2008-01-31 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome (hac) vector and human cell medicine comprising same
WO2008013737A2 (en) 2006-07-19 2008-01-31 University Of Florida Research Foundation, Inc. Compositions for reprogramming a cell and uses therefor
EP2053128A4 (en) 2006-08-15 2010-05-05 Ishihara Sangyo Kaisha INNOVATIVE METHOD OF USING MICROBIAL MUTANT
JP2008067693A (ja) * 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
WO2008033469A1 (en) 2006-09-15 2008-03-20 Children's Medical Center Corporation Methods for producing embryonic stem cells from parthenogenetic embryos
CA2684242C (en) 2007-03-23 2019-11-12 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CA2725953A1 (en) 2007-05-29 2008-12-11 Christopher B. Reid Methods for production and uses of multipotent cell populations, pluripotent cell populations, neuronal cell populations, and muscle cell populations
CN101802172A (zh) * 2007-05-30 2010-08-11 通用医疗公司 由体细胞产生多能细胞的方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
US9005966B2 (en) 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
US9206439B2 (en) * 2008-01-14 2015-12-08 Wisconsin Alumni Research Foundation Efficient oriP/EBNA-1 plasmid vector
WO2009092042A1 (en) 2008-01-18 2009-07-23 Nevada Cancer Institute Reprogramming of differentiated progenitor or somatic cells using homologous recombination
US20110061118A1 (en) * 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2954948A1 (en) 2008-06-04 2009-12-10 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
JP2011525794A (ja) 2008-06-26 2011-09-29 国立大学法人大阪大学 ｉＰＳ細胞の製造方法および製造キット
WO2010012077A1 (en) 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
KR101773345B1 (ko) 2008-08-12 2017-08-31 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 ｉＰＳ 세포의 생산 방법
WO2010028019A2 (en) * 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
US8268620B2 (en) 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU, J. et al., SCIENCE, 2007, vol.318, pp.1917-1920

Also Published As

Publication number Publication date
US9644184B2 (en) 2017-05-09
US20130189778A1 (en) 2013-07-25
US20180340150A1 (en) 2018-11-29
EP3447128A1 (en) 2019-02-27
CA2954948A1 (en) 2009-12-10
US8546140B2 (en) 2013-10-01
JP2020115881A (ja) 2020-08-06
CA2726990A1 (en) 2009-12-10
JP2014209912A (ja) 2014-11-13
EP2297307B1 (en) 2016-06-01
US20140038293A1 (en) 2014-02-06
KR20110036548A (ko) 2011-04-07
JP2018019684A (ja) 2018-02-08
AU2009256202A1 (en) 2009-12-10
WO2009149233A1 (en) 2009-12-10
ES2587395T3 (es) 2016-10-24
US9328332B2 (en) 2016-05-03
KR20160025045A (ko) 2016-03-07
US20100003757A1 (en) 2010-01-07
AU2009256202B2 (en) 2014-07-03
IL209740A0 (en) 2011-02-28
EP2297307A1 (en) 2011-03-23
EP3112456A1 (en) 2017-01-04
EP3279314A1 (en) 2018-02-07
DK2297307T3 (en) 2016-07-25
KR101871192B1 (ko) 2018-06-27
IL209740A (en) 2014-01-30
JP2018007667A (ja) 2018-01-18
CA2726990C (en) 2020-09-08
JP2011522540A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
KR101648019B1 (ko) 비-바이러스 접근법을 사용한 ｉＰＳ 세포의 생산 방법
KR101773345B1 (ko) ｉＰＳ 세포의 생산 방법
JP2011522540A5 (cg-RX-API-DMAC7.html)
KR20180105670A (ko) 벡터-프리 유도만능 줄기세포를 생성시키기 위한 방법 및 벡터
AU2015255253A1 (en) Methods for the production of ips cells
HK1262665A1 (en) Methods and vectors to produce vector free induced pluripotent stem cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150330

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151026

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150330

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160126

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20151026

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101000452

Request date: 20160126

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160225

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20160126

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20160126

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20150529

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20131107

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160401

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20160607

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20160304

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160808

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160809

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190718

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200715

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210715

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230628

Start annual number: 8

End annual number: 8